Weekly wrap of events of the week peppered with context, commentary and opinion by a superstar panel. Click here to support Newslaundry: http://bit.ly/paytokeepnewsfree Hosted on Acast. See acast.com/privacy for more information.
…
continue reading
Contenido proporcionado por Pharma and BioTech News and BioTech News. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Pharma and BioTech News and BioTech News o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !
¡Desconecta con la aplicación Player FM !
Pharma and Biotech Daily: Eli Lilly's $3 Billion Investment, FDA Guidelines, and Industry Job Opportunities
MP3•Episodio en casa
Manage episode 454569422 series 3478766
Contenido proporcionado por Pharma and BioTech News and BioTech News. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Pharma and BioTech News and BioTech News o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly's $3 billion investment in manufacturing capacity for tirzepatide is in the spotlight as compounding pharmacies challenge an FDA decision to end the drug shortage. Meanwhile, Amgen is making waves with a $1 billion investment, adding 370 jobs in North Carolina and potentially ramping up manufacturing for an obesity drug. In other news, Protara and CG Oncology are excited to share promising outcomes for bladder cancer treatments. The FDA has also outlined guidelines for accelerated reviews, aiming to clarify expectations after recent controversies. Additionally, Novo is making significant manufacturing investments, and the Trump administration's impact on biopharma continues to be a topic of discussion. Job opportunities in the industry are also something to keep an eye on.
…
continue reading
66 episodios
MP3•Episodio en casa
Manage episode 454569422 series 3478766
Contenido proporcionado por Pharma and BioTech News and BioTech News. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Pharma and BioTech News and BioTech News o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly's $3 billion investment in manufacturing capacity for tirzepatide is in the spotlight as compounding pharmacies challenge an FDA decision to end the drug shortage. Meanwhile, Amgen is making waves with a $1 billion investment, adding 370 jobs in North Carolina and potentially ramping up manufacturing for an obesity drug. In other news, Protara and CG Oncology are excited to share promising outcomes for bladder cancer treatments. The FDA has also outlined guidelines for accelerated reviews, aiming to clarify expectations after recent controversies. Additionally, Novo is making significant manufacturing investments, and the Trump administration's impact on biopharma continues to be a topic of discussion. Job opportunities in the industry are also something to keep an eye on.
…
continue reading
66 episodios
Todos los episodios
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.